Abstract
The optimal perioperative regimens for hepatocellular carcinoma (HCC) remains undefined. The combination of immune checkpoint inhibitor camrelizumab plus VEGFR2 tyrosine kinase inhibitor apatinib have been approved for treating advanced HCC. This study aimed to explore the efficacy and safety of perioperative (neoadjuvant and adjuvant) or postoperative (adjuvant) camrelizumab plus apatinib for resectable HCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
